Mucus Obstructed Mice for Biomarker and Drug Development

$471,159P01FY2012HLNIH

Univ Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications, trials & patents

Paper 38753513 Paper 38607917 Paper 38328091 Paper 38016030 Paper 37847709 Paper 37285404 Paper 37253009 Paper 36965846 Paper 36563691 Paper 36343590 Paper 36342131 Paper 35879412 Paper 35672320 Paper 35576754 Paper 35378080 Paper 35353667 Paper 35217407 Paper 35074895 Paper 35040594 Paper 35024721 Paper 35001665 Paper 34952795 Paper 34801592 Paper 34561347 Paper 34321216 Paper 34172469 Paper 34058148 Paper 34013253 Paper 33981120 Paper 33825493 Paper 33518807 Paper 33358825 Paper 33232302 Paper 33184236 Paper 33128895 Paper 33084300 Paper 33031744 Paper 32877585 Paper 32802823 Paper 32536510 Paper 32526206 Paper 32298651 Paper 32004030 Paper 31841399 Paper 31800264 Paper 31765597 Paper 31715083 Paper 31687423 Paper 31524632 Paper 31172770 Paper 31120356 Paper 31060800 Paper 31037119 Paper 30973754 Paper 30956355 Paper 30956354 Paper 30944166 Paper 30853717 Paper 30712400 Paper 30604462 Paper 30560893 Paper 30420506 Paper 30352166 Paper 30320206 Paper 30212240 Paper 29946004 Paper 29667749 Paper 29579396 Paper 29481209 Paper 29226024 Paper 29107074 Paper 29099608 Paper 29074490 Paper 29035122 Paper 28993619 Paper 28903557 Paper 28877023 Paper 28861466 Paper 28851744 Paper 28537592 Paper 28461493 Paper 28435155 Paper 28392603 Paper 28157412 Paper 28098322 Paper 28075361 Paper 28062483 Paper 27836957 Paper 27746581 Paper 27695137 Paper 27660374 Paper 27556943 Paper 27494700 Paper 27435107 Paper 27341489 Paper 27127933 Paper 27115955 Paper 27115951 Trial NCT03556683 Trial NCT01792271

Abstract

Mucus obstruction is a key pathogenic step in many major human ainways diseases, including COPD and CF. As part of the drug discovery process, it is extremely valuable to have a small animal model that will accelerate the transition from in vitro studies of target identification/validation to eariy proof-of-concept studies in humans. The (3ENaC mouse has been engineered to exhibit many of the features of muco-obstructive human airways diseases, expressing a disease-initiating transgene (PENaC) that drives ainA/ay surface dehydration. The ainways dehydration of the PENaC mouse triggers a sequence of intraluminal airways mucus plaque/plug formation, airways inflammation with macrophage activation, ain/vays remodeling, bacterial infection, and emphysema. In Project II, we propose to contribute to the tPPG goals and needs for drug development as follows: 1) test in vivo the novel biophysical/biochemical formulation of a two-gel mucus clearance system, focusing on relationships between the rate of delivery of hypertonic saline (HS) and mucus clearance responses; 2) develop novel measures of mucus properties that will serve as validated biomarkers to predict the magnitude of the ain/vay mucus burden, i.e., our therapeutic target, utilizing PENaC mouse lines of differing ainways Na+ transport/ainway surface dehydration; 3) test the hypothesis that secreted mucins (MUC5AC, MUCSB) are therapeutic targets with favorable risk:benefit ratios by genetic studies of MUC5AC and MUCSB -/- crosses with PENaC mice and pharmacologic (novel ketolides/macrolides) approaches; and 4) test the hypothesis that bacterial infection of mucus-obstructed ainways can be prevented or reversed by hydration/mucolytic therapies. Thus, Project II should provide important in vivo data as to the validity of our novel two-gel model of mucus transport, identify biomarkers for pharmacodynamic studies of mucus modification to speed drug development in both animals and the clinic, and assist Core A to identify relevant targets and novel therapies of muco-obstructive lung disease.

View original record on NIH RePORTER →